Page last updated: 2024-08-24

valsartan and Brain Vascular Disorders

valsartan has been researched along with Brain Vascular Disorders in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's1 (16.67)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG1
Chujo, M; Hashimoto, T; Ishigaki, M; Kohro, T; Yamazaki, T1
Angeli, F; Reboldi, G; Verdecchia, P1
Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM1
Hayashi, N; Inukai, T; Kometani, M; Nakao, K; Yamamoto, S1
Barclay, BW; Navarrete, AE; Sahota, P; Webb, RL; Wosu, NJ1

Trials

1 trial(s) available for valsartan and Brain Vascular Disorders

ArticleYear
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Clinical therapeutics, 2005, Volume: 27, Issue:5

    Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Obesity; Risk Factors; Tetrazoles; Valine; Valsartan

2005

Other Studies

5 other study(ies) available for valsartan and Brain Vascular Disorders

ArticleYear
Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
    Medicine, 2023, Nov-17, Volume: 102, Issue:46

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cerebrovascular Disorders; Heart Failure; Humans; Irbesartan; Losartan; Myocardial Infarction; Retrospective Studies; Telmisartan; Tetrazoles; Valsartan

2023
The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).
    Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:2

    Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Female; Health Surveys; Heart Failure; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan

2013
Hypertension and the J-curve phenomenon: implications for tight blood pressure control.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:2

    Topics: Antihypertensive Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hypertension; Male; Product Surveillance, Postmarketing; Tetrazoles; Valine; Valsartan

2013
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
    Arzneimittel-Forschung, 1997, Volume: 47, Issue:5

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Body Weight; Cardiomegaly; Cerebrovascular Disorders; Enalapril; Heart Rate; Hypertension; Male; Mesentery; Muscle Contraction; Organ Size; Rats; Rats, Inbred SHR; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan

1997
Protective effects of valsartan and benazeprilat in salt-loaded stroke-prone spontaneously hypertensive rats.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 1998, Volume: 20, Issue:7

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cerebrovascular Disorders; Genetic Predisposition to Disease; Heart Rate; Hypertension; Infusion Pumps; Kidney; Myocardium; Proteinuria; Rats; Rats, Inbred SHR; Renin; Renin-Angiotensin System; Sodium Chloride; Tetrazoles; Valine; Valsartan

1998